» Articles » PMID: 26170632

Phenolic Indeno[1,2-b]indoles As ABCG2-selective Potent and Non-toxic Inhibitors Stimulating Basal ATPase Activity

Abstract

Ketonic indeno[1,2-b]indole-9,10-dione derivatives, initially designed as human casein kinase II (CK2) inhibitors, were recently shown to be converted into efficient inhibitors of drug efflux by the breast cancer resistance protein ABCG2 upon suited substitutions including a N (5)-phenethyl on C-ring and hydrophobic groups on D-ring. A series of ten phenolic and seven p-quinonic derivatives were synthesized and screened for inhibition of both CK2 and ABCG2 activities. The best phenolic inhibitors were about threefold more potent against ABCG2 than the corresponding ketonic derivatives, and showed low cytotoxicity. They were selective for ABCG2 over both P-glycoprotein and MRP1 (multidrug resistance protein 1), whereas the ketonic derivatives also interacted with MRP1, and they additionally displayed a lower interaction with CK2. Quite interestingly, they strongly stimulated ABCG2 ATPase activity, in contrast to ketonic derivatives, suggesting distinct binding sites. In contrast, the p-quinonic indenoindoles were cytotoxic and poor ABCG2 inhibitors, whereas a partial inhibition recovery could be reached upon hydrophobic substitutions on D-ring, similarly to the ketonic derivatives.

Citing Articles

Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2).

da Silva Zanzarini I, Henrique Kita D, Scheiffer G, Karoline Dos Santos K, de Paula Dutra J, Augusto Pastore M Bioorg Chem. 2024; 146:107283.

PMID: 38513324 PMC: 11069345. DOI: 10.1016/j.bioorg.2024.107283.


POCl mediated one-pot deoxygenative aromatization and electrophilic chlorination of dihydroxy-2-methyl-4-oxo-indeno[1,2-]pyrroles.

Nasuhipur F, Ghasemi Z, Poupon M, Dusek M RSC Adv. 2023; 13(26):17812-17816.

PMID: 37323449 PMC: 10261912. DOI: 10.1039/d3ra02515b.


A Novel Flow Cytometry-Based Assay for the Identification of HCN4 CNBD Ligands.

Wojciechowski M, Schreiber S, Jose J Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242492 PMC: 10224427. DOI: 10.3390/ph16050710.


Development of Simple and Accurate in Silico Ligand-Based Models for Predicting ABCG2 Inhibition.

Huang S, Gao Y, Zhang X, Lu J, Wei J, Mei H Front Chem. 2022; 10:863146.

PMID: 35665065 PMC: 9159808. DOI: 10.3389/fchem.2022.863146.


Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.

Henrique Kita D, Guragossian N, Fatima Zattoni I, Rotuno Moure V, Gomes de Moraes Rego F, Lusvarghi S Sci Rep. 2021; 11(1):1788.

PMID: 33469044 PMC: 7815716. DOI: 10.1038/s41598-020-79892-w.


References
1.
Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

2.
Arnaud O, Boumendjel A, Geze A, Honorat M, Matera E, Guitton J . The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. Eur J Cancer. 2011; 47(4):640-8. PMC: 6936733. DOI: 10.1016/j.ejca.2010.11.019. View

3.
Gratz A, Gotz C, Jose J . A CE-based assay for human protein kinase CK2 activity measurement and inhibitor screening. Electrophoresis. 2010; 31(4):634-40. DOI: 10.1002/elps.200900514. View

4.
Natarajan K, Xie Y, Baer M, Ross D . Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012; 83(8):1084-103. PMC: 3307098. DOI: 10.1016/j.bcp.2012.01.002. View

5.
Telbisz A, Muller M, Ozvegy-Laczka C, Homolya L, Szente L, Varadi A . Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim Biophys Acta. 2007; 1768(11):2698-713. DOI: 10.1016/j.bbamem.2007.06.026. View